The Dermapace system represents a significant advancement in the treatment of chronic diabetic foot ulcers (DFUs). FDA-approved for its focused extracorporeal shockwave therapy (ESWT), it offers a non-invasive solution for patients struggling with DFUs that have not responded to traditional wound care. Utilizing pulsed acoustic cellular expression (PACE®) technology, Dermapace stimulates tissue repair, aiming to...Read More